MERZ NAMED THE TOP AESTHETICS COMPANY BY AESTHETIC EVERYTHING®. Merz North America CEO Bob Rhatigan named the Top Aesthetics CEO Cellfina® and Ultherapy® Also Recognized as Top Procedures
Merz North America, Inc. announced today that Merz has been recognized by Aesthetic Everything® as the Top Aesthetics Company and the winner of four other 2017 Diamond Crystal Awards, including the recognition of Cellfina® as the Top Minimally Invasive Procedure and Ultherapy® as a Top Non-Surgical Procedure in the industry. In addition, Merz North America CEO Bob Rhatigan was named the Top Aesthetics CEO.
Aesthetic Everything®, the largest social network built exclusively for aesthetic professionals, announces winners of the Diamond Crystal Awards annually. The awards applaud outstanding achievement in the aesthetic industry in the areas of treatment, products, management and leadership. Merz was recognized across numerous award categories, notably:
- Merz named the Top Aesthetics Company
- Bob Rhatigan named the Top Aesthetics CEO
- Cellfina® named the Top Minimally Invasive Procedure
- Ultherapy® recognized as a Top Non-Surgical Procedure
- Merz North America Senior Director of Marketing Roberto Casas-Rudbeck recognized as a Top Aesthetics Executive
“At Merz, we work hard everyday to understand the needs of physicians and patients to develop new and innovative products and treatments that deliver meaningful results,” said Bob Rhatigan, Merz North America CEO. “These awards highlight the dedication and commitment of all of our employees to deliver on our mission to help patients live better, feel better and look better. We are proud that Cellfina® and Ultherapy® are the only FDA-cleared procedures for their respective indications, and that they are clinically proven.”
The Cellfina® System is the first long-lasting, minimally invasive solution proven to smooth away cellulite dimples for at least three years in a single treatment. The Cellfina® System combines highly advanced, proprietary technology with a well-established procedure called subcision to treat the structural cause of cellulite dimples. According to market research, 78 percent of women in the U.S. have cellulite that would qualify as treatable with the Cellfina® System1. The Cellfina® System is currently available nationwide at more than 250 exclusive aesthetic practices. For more information on the Cellfina® System, visit www.cellfina.com.
Ultherapy® is the first and only treatment FDA-cleared to non-invasively lift the eyebrow, neck, and chin, and to improve lines and wrinkles on the décolletage. Ultherapy® is also the only cosmetic procedure to use ultrasound imaging, which allows physicians to see the layers of tissue targeted during the treatment to ensure the energy is deposited where it will be most beneficial. This unique technology is supported by more than 50 clinical studies, 60 published peer-reviewed papers, and over 100 patents. For more information on Ultherapy®, visit www. ultherapy.com.
The non-invasive Ultherapy® procedure is U.S. FDA-cleared to lift skin on the neck, on the eyebrow and under the chin as well as to improve lines and wrinkles on the décolletage. The most common side effects reported in clinical trials were redness, swelling, pain and transient nerve effects. Reported adverse events from post-marketing surveillance are available in the Instructions for Use (IFU). Please see the IFU for product and safety information, including a full list of these events at ultherapy.com/IFU.
About Cellfina® System
The Cellfina® System is intended for long-term improvement in the appearance of cellulite dimples in the buttocks and thigh areas of adult females. Safety and effectiveness in other anatomical areas have not been established. The most common side effects reported were soreness, tenderness, and bruising. The Cellfina® System is only available through a licensed physician. For product and safety information, visit cellfina.com/IFU.
About Merz North America, Inc.
Merz North America, Inc. is a specialty healthcare company dedicated to the development and marketing of innovative quality products for physicians and patients across the United States and Canada. Merz products are distributed through two divisions, Aesthetics and Neurosciences, and are developed with the goal of improving patients’ health and quality of life by delivering therapies that bring about real progress. Merz is a privately-held company based in Raleigh, North Carolina To learn more about Merz North America, Inc., please visit www.merzusa.com.
With approximately 3,000 employees and 34 subsidiaries worldwide, Merz is a global leader in Aesthetics and Neurotoxins. Privately held for more than 100 years, the company is distinguished by its in-house research and development, solid financial strength and continuous growth. Complementing its unique portfolio of products for minimally invasive and non-invasive skin rejuvenation and tightening, Merz also develops neurotoxin therapy for the treatment of movement disorders. Skincare products and a range of OTC medicines are also included in offerings from the company, which is headquartered in Frankfurt, Germany. In fiscal year 2016/17, the Merz Pharma Group generated revenue of EUR 1,023.2 million. More information is available at www.merz.com.
09.21.2017 [ 0 KB ]
Merz North America